Why China’s rise needs to be taken with a pinch of salt
A closer look at the numbers that paint China as accelerating towards global biopharma dominance and you will find indications…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
Why the CNS boom owes its success to breakthroughs in neurological pathologies
Experts say we can thank an improved understanding of the biology behind central nervous system (CNS) diseases for the resurgence…
-
Peptide innovator says the drug class is due for a rethink
The FDA’s acceptance of several untested peptides for human use has left one drug innovator calling for a greater clarity…
-
MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones
The US policy of Most Favoured Nation (MFN) pricing has raised uncertainty in European markets reluctant to raise drug prices…
-
Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive
Following multibillion dollar asset acquisitions and artificial intelligence (AI)-centred deals, Servier’s head of business development outlines how one of France’s…
-
Podcast: HLTH Europe and BIO key trends rundown
June was a busy month for Pharmaceutical Technology’s editorial team, with journalists attending several key conferences with reach across the…
-
Beyond the GLP-1RA weight loss ceiling
On 21 May 21, 2026, Eli Lilly’s retatrutide achieved a historic first; as of June 2026, it is the only…
-
BIO 2026: Former FDA staff question agency’s “radical transparency” approach
The US Food and Drug Administration (FDA)’s “radical transparency” approach may have provided a more direct method, but it has…
-
BIO 2026: How NIH cuts have threatened US competitiveness against China
Funding cuts at US federal agencies have compounded threats to the US’s predominance in global biopharma as an ascendant Chinese…
-
BIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents
NVIDIA has unveiled the BioNeMo agent toolkit, a package of tools for life sciences R&D designed specifically for use by…